Evidence map›Paper›PMID 35305459›Full record

ArticlePublic health2022

The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.

A Gamkrelidze, S Handanagic, S Shadaker, A Turdziladze, M Tsereteli, V Getia, A Aslanikashvili, S Surguladze, L Gvinjilia, T Kuchuloria and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

A GamkrelidzeNational Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.
S HandanagicDivision of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC, Atlanta, United States. Electronic address: ndv9@cdc.gov.
S ShadakerDivision of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC, Atlanta, United States.
A TurdziladzeNational Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.
M TsereteliNational Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.
V GetiaNational Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.
A AslanikashviliNational Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.
S SurguladzeNational Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.
L GvinjiliaCenters for Disease Control and Prevention, Eastern Europe and Central Asia Regional Office, Tbilisi, Georgia.
T KuchuloriaHepatitis Team in Georgia, Task Force for Global Health, Atlanta, Georgia, USA.
I TskhomelidzeHepatitis Team in Georgia, Task Force for Global Health, Atlanta, Georgia, USA.
P A ArmstrongDivision of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC, Atlanta, United States.
National Center for Disease Control and Public Health · GENational Center for HIV/AIDS Viral Hepatitis STD and TB Prevention · USThe Task Force for Global Health · USCenters for Disease Control and Prevention · UG

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

objectivesIn 2015, the Republic of Georgia initiated a National Hepatitis C Elimination Program, with a goal of 90% reduction in prevalence of chronic hepatitis C virus (HCV) infections by 2020. In this article, we explore the impact of the COVID-19 pandemic on the 2020 hepatitis C cascade of care in Georgia. STUDY

designRetrospective analytic study.

methodsWe used a national screening registry that includes hospitals, blood banks, antenatal clinics, harm reduction sites, and other programs and services to collect data on hepatitis C screening. A separate national treatment database was used to collect data on viremia and diagnostic testing, treatment initiation, and outcome including testing for and achieving sustained virologic response (SVR). We used these databases to create hepatitis C care cascades for 2020 and 2019. Bivariate associations for demographic characteristics and screening locations per year and care cascade comparisons were assessed using a chi-squared test.

resultsIn 2020 compared to 2019, the total number of persons screened for HCV antibodies decreased by 25% (from 975,416 to 726,735), 59% fewer people with viremic infection were treated for HCV infection (3188 vs. 7868), 46% fewer achieved SVR (1345 vs. 2495), a significantly smaller percentage of persons with viremic infection initiated treatment for HCV (59% vs. 62%), while the percentage of persons who achieved SVR (99.2% vs. 99.3%) remained stable.

conclusionsThe COVID-19 pandemic had a negative impact on the hepatitis C elimination program in Georgia. To ensure Georgia reaches its elimination goals, mitigating unintended consequences of delayed diagnosis and treatment of hepatitis C due to the COVID-19 pandemic are paramount.

Indexed as

COVID-19Hepatitis CHepatitis C, ChronicAntiviral AgentsFemaleGeorgiaGeorgia (Republic)HepacivirusHumansPandemicsPregnancyRetrospective StudiesAntiviral AgentsCascade of careCOVID-19GeorgiaHCV eliminationHepatitis C (HCV)

Identifiers

PMID35305459
PMCPMC9004234
OpenAlexW4210873561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.